U.S. markets open in 1 hour 17 minutes
  • S&P Futures

    3,884.00
    +16.50 (+0.43%)
     
  • Dow Futures

    31,518.00
    +160.00 (+0.51%)
     
  • Nasdaq Futures

    13,115.00
    +59.75 (+0.46%)
     
  • Russell 2000 Futures

    2,248.90
    +19.80 (+0.89%)
     
  • Crude Oil

    60.53
    +0.78 (+1.31%)
     
  • Gold

    1,718.70
    -14.90 (-0.86%)
     
  • Silver

    26.47
    -0.41 (-1.52%)
     
  • EUR/USD

    1.2053
    -0.0035 (-0.29%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    23.28
    -0.07 (-0.30%)
     
  • GBP/USD

    1.3956
    -0.0000 (-0.00%)
     
  • USD/JPY

    106.8700
    +0.1600 (+0.15%)
     
  • BTC-USD

    52,241.16
    +3,247.26 (+6.63%)
     
  • CMC Crypto 200

    1,042.58
    +54.48 (+5.51%)
     
  • FTSE 100

    6,662.87
    +49.12 (+0.74%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

WAVE Life Sciences: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 0.1% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 41.89% over the past year to ($0.86), which missed the estimate of ($0.69).

Revenue of $3,450,000 up by 17.79% year over year, which missed the estimate of $11,550,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

WAVE Life Sciences hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 09, 2020

View more earnings on WVE

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/avh2x78g

Recent Stock Performance

Company's 52-week high was at $39.98

52-week low: $6.61

Price action over last quarter: down 22.17%

Company Description

WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.